Studies concerning the development of radiopharmaceuticals based on the Tc (I) carbonyl
core are considered from the coordination-chemical viewpoint. The coordination behavior of …

Diagnostic and therapeutic nuclear medicine relies heavily on radiometal nuclides. The
most widely used and well-known radionuclide is technetium-99m (99mTc), which has …

Targeted radionuclide therapy (TRNT) is an ever-expanding field of nuclear medicine that
provides a personalised approach to cancer treatment while limiting toxicity to normal …

Organometallic complexes of fac-tricarbonylrhenium have been shown to exhibit anticancer
properties. Anthrapyrazole anticancer agents act as DNA intercalators and topoisomerase …

With the long-term goal of developing theranostic agents for applications in nuclear
medicine, in this work we evaluated the well-known NOTA and NODAGA chelators as …

Introduction The aim of this work was to develop diagnostic (99m Tc) and therapeutic (186
Re) agents for targeting somatostatin receptor (SSTR)-positive neuroendocrine tumors …

Hexahistidine tags (His-tags), incorporated into recombinant proteins to facilitate purification
using metal-affinity chromatography, are useful binding sites for radiolabeling with [99mTc …

The somatostatin receptor subtype 2 (SSTR2) is often highly expressed on neuroendocrine
tumors (NETs), making it a popular in vivo target for diagnostic and therapeutic approaches …

Introduction A somatostatin receptor (SSTR)-targeting antagonist peptide (sst 2-ANT) was
radiolabeled with 99m Tc tricarbonyl via a tridentate [N, S, N]-type ligand (L) to develop a …

A novel bisphosphonate, 1-(3-aminopropylamino) ethane-1, 1-diyldiphosphonic acid (3),
was coupled to the tridentate chelators di-2-picolylamine, 2-picolylamine-N-acetic acid …